Skip to main content

So Long

Joshua Sharfstein, the deputy commissioner at FDA, is leaving the agency after 21 months on the job, reports the Wall Street Journal. Sharfstein will be the new Maryland secretary of health and mental hygiene. His departure was reported first by a tweet from Congressional Quarterly's HealthBeat, prompting The In Vivo Blog speculate that Sharfstein's leaving likely as something to do with the goings-on on Capitol Hill. "We see Sharfstein's departure means first and foremost as a change in positioning for FDA facing the incoming Republican majority in the House," says Michael McCaughan at The In Vivo Blog. The Journal says that this may affect the release of the medical-device approval guidelines. "Any significant restrictions will likely cause a backlash in the device industry, which has allies among Republican House leaders," the Journal adds.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.